PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose PIK3CA, encoding for subunit p110a of phosphatidylinositol 3 kinase, is frequently mutated in breast cancer. PIK3CAmutation was predictive for pathological complete response (pCR) in human epidermal growth factor 2 positive breast cancer. This study explores the association of PIK3CA mutation and pCR in triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy. Materials and Methods A total of 92 patients with TNBC derived from a prospectively randomized phase II trial GeparSixto study (NCT01426880). Exon 9 and exon 20 of PIK3CA mutations were evaluated by using classical Sanger method with formalin-fixed paraffin-embedded tumor tissues. Results Seven of 90 tumors (7.8%) were detectable with a PIK3CA H1047R mutation. Overall, PIK3CA H1047R mutation was significantly associated with a lower pCR rate (14.3% vs. 56.6%; odds ratio, 0.128; 95% confidence interval [CI], 0.015 to 1.108; p=0.047). In carboplatin- containing treatment patients, H1047R mutation trended to predict a lower pCR rate (20% vs. 62.5%; p=0.146). In a multivariable analysis, H1047R mutation trended to predict a lower pCR rate (hazard ratio, 0.1; 95% CI, 0.01 to 1; p=0.056). Conclusion TNBC with a PIK3CA H1047R mutation was less likely to achieve pCR after anthracyclinebased neoadjuvant chemotherapy. Development of H1047R mutant selective inhibitors might be helpful to conquer this subtype of breast cancer.
Abstract
Purpose PIK3CA, encoding for subunit p110a of phosphatidylinositol 3 kinase, is frequently mutated in breast cancer. PIK3CAmutation was predictive for pathological complete response (pCR) in human epidermal growth factor 2 positive breast cancer. This study explores the association of PIK3CA mutation and pCR in triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy. Materials and Methods A total of 92 patients with TNBC derived from a prospectively randomized phase II trial GeparSixto study (NCT01426880). Exon 9 and exon 20 of PIK3CA mutations were evaluated by using classical Sanger method with formalin-fixed paraffin-embedded tumor tissues. Results Seven of 90 tumors (7.8%) were detectable with a PIK3CA H1047R mutation. Overall, PIK3CA H1047R mutation was significantly associated with a lower pCR rate (14.3% vs. 56.6%; odds ratio, 0.128; 95% confidence interval [CI], 0.015 to 1.108; p=0.047). In carboplatin- containing treatment patients, H1047R mutation trended to predict a lower pCR rate (20% vs. 62.5%; p=0.146). In a multivariable analysis, H1047R mutation trended to predict a lower pCR rate (hazard ratio, 0.1; 95% CI, 0.01 to 1; p=0.056). Conclusion TNBC with a PIK3CA H1047R mutation was less likely to achieve pCR after anthracyclinebased neoadjuvant chemotherapy. Development of H1047R mutant selective inhibitors might be helpful to conquer this subtype of breast cancer.
참고문헌 (26)
- Foulkes WD, "Triple-negative breast cancer", N Engl J Med, 363, pp.1938~1948 (2010)
- Bauer KR, "Descriptive analysis of estrogen receptor(ER)-negative, progesterone receptor(PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype : a population-based study from the California cancer Registry", Cancer, 109, pp.1721~1728 (2007)
- Liu P, "Targeting the phosphoinositide 3-kinase pathway in cancer", Nat Rev Drug Discov, 8, pp.627~644 (2009)
- Vinayak S, "mTOR inhibitors in the treatment of breast cancer", Oncology(Williston Park), 27, pp.38~44 (2013)
- Samuels Y, "High frequency of mutations of the PIK3CA gene in human cancers", Science, 304, pp.554~ (2004)
- Isakoff SJ, "Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells", Cancer Res, 65, pp.10992~11000 (2005)
- Bader AG, "Cancer-specific mutations in PIK3CA are oncogenic in vivo", Proc Natl Acad Sci U S A, 103, pp.1475~1479 (2006)
- Ling Deng, "Prevalence and Prognostic Role of PIK3CA", AKT1 Mutations in Chinese Breast Cancer Patients, 2019, pp.51(1), 128~140[DOI]
- Zardavas D, "Tumor PIK3CA genotype and prognosis : a pooled analysis of 4, 241 patients(pts)with early-stage breast cancer(BC)", J Clin Oncol, 33(15 Suppl), pp.516~ (2015)
- Kalinsky K, "PIK3CA mutation associates with improved outcome in breast cancer", Clin Cancer Res, 15, pp.5049~5059 (2009)
- Campbell IG, "Mutation of the PIK3CA gene in ovarian and breast cancer", Cancer Res, 64, pp.7678~7681 (2004)
- Loibl S, "PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer : pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab", Ann Oncol, 27, pp.1519~1525 (2016)
- Li SY, "PIK3CA mutations in breast cancer are associated with poor outcome", Breast Cancer Res Treat, 96, pp.91~95 (2006)
- Kaufmann M, "Recommendations from an international expert panel on the use of neoadjuvant(primary)systemic treatment of operable breast cancer : an update", J Clin Oncol, 24, pp.1940~1949 (2006)
- Cortazar P, "Pathological complete response and long-term clinical benefit in breast cancer : the CTNeoBC pooled analysis", Lancet, 384, pp.164~172 (2014)
- Denkert C, "Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer", J Clin Oncol, 28, pp.105~113 (2010)
- Loibl S, "PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2(her2)therapy in primary HER2-overexpressing breast cancer", J Clin Oncol, 32, pp.3212~3220 (2014)
- McShane LM, "REporting recommendations for tumor MARKer prognostic studies(REMARK)", Breast Cancer Res Treat, 100, pp.229~235 (2006)
- Denkert C, "Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triplenegative primary breast cancers", J Clin Oncol, 33, pp.983~991 (2015)
- Zhao JJ, "The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells", Proc Natl Acad Sci U S A, 102, pp.18443~18448 (2005)
- Baselga J, "Biomarker analyses in CLEOPATRA : a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer", J Clin Oncol, 32, pp.3753~3761 (2014)
- Berns K, "A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer", Cancer Cell, 12, pp.395~402 (2007)
- Loibl S, "Mutational Diversity and therapy response in breast cancer : a sequencing analysis in the neoadjuvant GeparSepto trial", Clin Cancer Res, 25, pp.3986~3995 (2019)
- Meyer DS, "Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R", Oncogenesis, 2, pp.e74~ (2013)
- von Minckwitz G, "Neoadjuvant carboplatin in patients with triplenegative and HER2-positive early breast cancer(GeparSixto;GBG 66) : a randomised phase 2 trial", Lancet Oncol, 15, pp.747~756 (2014)
- Janku F, "PIK3CA mutation H1047R is associated with response to PI3K", AKT, Cancer Res, pp.2013, 73[DOI]